Traders should monitor the AACR poster presentations for any unexpected positive signals in efficacy or safety, particularly in the Phase 3 QOL data, which could support future regulatory or partnership discussions. However, absence of hard efficacy endpoints limits near-term catalyst strength.
Price Chart
Executive Summary
BriaCell Therapeutics will present four posters at the 2026 AACR Annual Meeting, including Phase 3 quality-of-life data for its Bria-IMT therapy in metastatic breast cancer and preclinical results for its next-generation Bria-OTS+ platform. The data highlight potential clinical benefits and immune activation, though no new efficacy endpoints or survival data are disclosed.
Key Facts
- BriaCell will present four posters at the 2026 AACR Annual Meeting (April 17–22).
- One poster includes Phase 3 quality-of-life (QOL) data from the Bria-IMT + checkpoint inhibitor trial in late-stage metastatic breast cancer.
- Two posters present further analyses of Phase 2 data, including biomarker findings related to PD-L1 in circulating cells.
- One poster details preclinical data for Bria-OTS+, showing activation of both innate and adaptive immunity.
- No overall survival, progression-free survival, or objective response rate data are reported in this release.
Financial Impact
No direct financial impact disclosed; potential indirect impact via investor sentiment from clinical data visibility
Risk Factors
- Forward-looking statements with no guarantee of clinical success
- Lack of pivotal efficacy data (e.g., survival outcomes) in the upcoming presentations
- Low market cap ($9M) increases volatility risk ahead of data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258061 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | Press Release | $0.8800 $1.02 | ▲ +16.02% | ▲ +13.76% | — |
Aug 5, 2026 11w ago | Press Release | $0.8600 | awaiting T+20 | — | — |
Jul 16, 2026 14w ago | Press Release | $0.9000 $0.8250 | ▼ −8.33% | ▼ −11.95% | — |
May 26, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 22, 2026 22w ago | Press Release | — | awaiting T+20 | — | — |
May 13, 2026 23w ago | Press Release | $1.05 $0.6999 | ▼ −33.34% | ▼ −32.73% | — |
May 6, 2026 24w ago | Press Release | — | awaiting T+20 | — | — |
Apr 21, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Apr 20, 2026 27w ago | Press Release | — | awaiting T+20 | — | — |
Mar 18, 2026 31w ago | Press Release | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers